series-a
Stage
2025
Founded
2
Investors
About
Leal Therapeutics develops neuro-metabolic therapeutics for central nervous system disorders, pursuing antisense oligonucleotides and small molecules that target metabolic pathways underlying diseases such as ALS and schizophrenia.
Explore Leal Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.